BeyondSpring of New York enrolled the first patient in the China arm of a global Phase II/III clinical trial of plinabulin for the prevention of chemotherapy-induced neutropenia (CIN). Earlier this year, plinabulin started a China Phase III clinical trial as a immuno-oncology agent in patients with non-small cell lung cancer. BeyondSpring expects to report top line results later in 2017 from the Phase II portion of the neutropenia trial.
Source: China Biotoday
